Some see homelessness as more free than living in a house or apartment, and prefer being in nature, as well as away from other people. Some may have had a traumatic experience in a house or apartment, such as a fire, and feel safer outside, being able to survey their surroundings. Challenges
The basic problem of homelessness is the need for personal shelter, warmth, and safety. Other difficulties include:

Hygiene and sanitary facilities
Hostility from the public and laws against urban vagrancy
Cleaning and drying of clothes
Obtaining, preparing, and storing food
Keeping contact with friends, family, and government service providers without a permanent location or mailing address
Medical problems, including issues caused by an individuals homeless state (e.g., hypothermia or frostbite from sleeping outside in cold weather), or issues which are exacerbated by homelessness due to lack of access to treatment (e.g., mental health and the individual not having a place to store prescription drugs)
Personal security, quiet, and privacy, especially for sleeping, bathing, and other hygiene activities
Safekeeping of bedding, clothing, and possessions, which may have to be carried at all timesPeople experiencing homelessness face many problems beyond the lack of a safe and suitable home.
Interstitial lung disease and pneumonitis, including cases resulting in death, have been reported with trastuzumab deruxtecan. History
The FDA approved trastuzumab deruxtecan based on the results of one clinical trial enrolling 184 female participants with HER2-positive, unresectable and/or metastatic breast cancer who had received two or more prior anti-HER2 therapies in the metastatic setting. These participants were heavily pretreated in the metastatic setting, receiving between two and 17 therapies prior to receiving trastuzumab deruxtecan. Participants in the clinical trial received trastuzumab deruxtecan every three weeks and tumor imaging was obtained every six weeks. The overall response rate was 60.3%, which reflects the percentage of participants who had a certain amount of tumor shrinkage with a median duration of response of 14.8 months.Efficacy was evaluated in a multicenter, open-label, randomized trial (DESTINY-Gastric01, NCT03329690) in participants with HER2-positive locally advanced or metastatic gastric or GEJ adenocarcinoma who had progressed on at least two prior regimens, including trastuzumab, a fluoropyrimidine- and a platinum-containing chemotherapy. A total of 188 participants were randomized (2:1) to receive trastuzumab deruxtecan 6.4 mg/kg intravenously every three weeks or physician’s choice of either irinotecan or paclitaxel monotherapy.Efficacy was based on DESTINY-Breast03 (NCT03529110), a multicenter, open-label, randomized trial that enrolled 524 participants with HER2-positive, unresectable, and/or metastatic breast cancer who received prior trastuzumab and taxane therapy for metastatic disease or developed disease recurrence during or within six months of completing neoadjuvant or adjuvant therapy.